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Abstract
Background: Resistance training of peripheral muscles has been recommended in order to increase muscle
strength in patients with Chronic Obstructive Pulmonary Disease (COPD). However, whether peripheral muscle
strength is associated with exercise performance (EP) and physical activity in daily life (PADL) in these patients
needs to be investigated.
The aim of this study is to evaluate whether strength of the quadriceps muscle (QS) is associated with EP and daily
PADL in patients with COPD.
Methods: We studied patients with COPD (GOLD A-D) and measured maximal isometric strength of the left QS.
PADL was measured for 7 days with a SenseWear-Pro® accelerometer. EP was quantified by the 6-minute walk
distance (6MWD), the number of stands in the Sit-to-Stand Test (STST), and the handgrip-strength. Univariate and
multivariate analyses were used to examine possible associations between QS, PADL and EP.
Results: In 27 patients with COPD with a mean (SD) FEV1 of 37.6 (17.6)% predicted, QS was associated with 6MWD,
STST, and handgrip-strength but not with PADL. Multiple linear regression analyses showed that QS was
independently associated with the 6MWD (β = 0.42, 95% CI 0.09 to 0.84, p = 0.019), STST (β = 0.50, 95% CI 0.11 to
0.86, p = 0.014) and with handgrip-strength (β = 0.45, 95% CI 0.05 to 0.84, p = 0.038).
Conclusions: Peripheral muscle strength may be associated with exercise performance but not with physical
activity in daily life. This may be due to the fact that EP tests evaluate patients’ true abilities while PADL
accelerometers may not.
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Background
Physical inactivity in daily life is a prominent feature in
patients with Chronic Obstructive Pulmonary Disease
(COPD) [1-4] and the amount of physical activity in
daily life (PADL) gradually declines with the severity of
disease [4-6]. Several studies have demonstrated that
the level of PADL is associated with the number of
hospitalizations [7-9] and is known as the strongest pre-
dictor of all-cause mortality [7,10] in patients with
COPD. As a result, both the American Thoracic Society
and the European Respiratory Society [11] stressed the
fact that long-term self-management and adherence to
exercise at home should be the primary goals of pul-
monary rehabilitation programs (PR).
One of the extrapulmonary manifestations of COPD is
skeletal muscle dysfunction [12-15] and therefore resist-
ance training of peripheral muscles has been strongly rec-
ommended during pulmonary rehabilitation (PR) [16,17].
As there is compelling evidence highlighting the role of
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muscular strength in exercise performance (EP) in pa-
tients with COPD [13,18-22], it seems reasonable to
assume that enhanced peripheral muscle strength sub-
sequently leads to improvements in performing daily
tasks and participating in daily life activities. However,
it is currently unclear whether peripheral muscle
strength is associated with daily physical activity levels
(PAL) in patients with COPD. The methods used to
assess PADL in previous studies were very different
[8,23-30]. Only very few data are available from studies
assessing PADL objectively with a multi-dimensional
accelerometer. Furthermore, the results of these studies
were conflicting: five studies [8,23-26] demonstrated a
positive association between quadriceps strength (QS)
and PADL whereas four studies [27-30] did not.
Investigating the role of peripheral muscle strength
and its contribution to exercise tolerance may be im-
portant for understanding the pathophysiology of exer-
cise limitation and reduced PADL in patients with
COPD and may help to define the best therapeutic ap-
proach in these patients. Therefore, the purpose of the
present study was to examine the relationship between
QS and EP (reflected by the 6-minute walk distance
(6MWD), the number of stands in the Sit-to-Stand Test
(STST), handgrip-strength) and PADL as assessed by a
multi-dimensional accelerometer (the SenseWear Pro®
armband) in patients with COPD.
Methods
Study design
A cross-sectional study in patients with COPD (GOLD-
classification A-D) was performed.
Patients with COPD referred to the Pulmonary Division,
University Hospital of Zurich, Switzerland between March
and September 2012 were considered for participation in
the study. The inclusion criteria for patients were: male
and female subjects aged 40–75 years and confirmed
COPD according to GOLD-guidelines [31]. The partici-
pants were included in a convenience sample. The study
was approved by the Research Ethics Committee of the
University Hospital of Zurich, Switzerland (KEK-ZH-NR:
2011-0106/1) and written informed consent was obtained
from all patients.
Sample size calculation
The sample size calculation was based on the results
reported by Mador and colleagues [24].
We calculated that the minimum sample size needed
to detect a significant association between QS and PADL
with 80% power, a significance level of .05 and a hypo-
thetical drop-out-rate due to technical problems of 25%,
would be 23 subjects.
Measurements
Pulmonary function
Spirometry, whole-body plethysmography and diffusion
capacity measurements were performed according to the
American Thoracic Society (ATS) and the European Re-
spiratory Society (ERS) guidelines with a commercially
available system [32,33].
Six-minute-walk-test (6MWT)
Patients performed the 6MWT following pulmonary func-
tion testing. The 6MWT was conducted in accordance
with the ATS guidelines [34]. None of the patients used a
walking aid in daily life or during the test. The 6MWT
was performed on a 30-meter indoor track by an experi-
enced investigator using standardized encouragement
strategy [35]. Subjects were allowed to rest if needed. Mea-
surements of SpO2 were performed using a finger pulse
oximeter (TuffSat™, DatexOhmeda, USA, and PureLight®
8000, Nonin Medical Inc., Sweden). SpO2, dyspnoea
and leg fatigue [36] were assessed after a resting period
of 5 minutes immediately after the test.
Sit-to-stand-test
The STST was performed in a distraction-protected envir-
onment. A standard chair (46 cm height) without arm
supports was used. Subjects were asked to stand up from
and sitting down on the chair with arms stationary on the
hips, repeating the procedure as many times as possible
within 1 minute at a patient-defined pace. The patients
had to stand in full extension (knee and hip extension)
and sitting in a position with their knees at 90° flexion.
The number of completed repetitions was counted [37].
Handgrip-strength
Handgrip-strength of the dominant hand was measured
with a dynamometer (Hand-Dynamometer Bremshey;
Accell Fitness, Almere, Netherlands) as described else-
where [38].
Quadriceps strength
Isometric strength of the left quadriceps muscle group
was measured during maximum voluntary contraction
(QMVC) with the hips and knees in 90° flexion. QMVC
was defined as the highest mean strength that could be
sustained over 3 s and expressed in Newton-meters (Nm).
Strength was measured with a strap looped around the
left leg just proximal to the ankle and connected to a
strain gauge. The strain gauge was connected to the
Interface series SM S-Type Load Cell (U.S. & Metric)
and the Nexus-10™ device (TMS International BV,
Netherlands). All subjects were studied while seated in
an adjustable straight-backed chair. Three maximum
voluntary contractions were recorded for each patient.
The average of the three scores was used for further
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analysis. After each test the patients were able to rest for
a period of two minutes.
Physical activity in daily life
Daily Physical Activity was measured by a multisensor
accelerometer (SenseWear Pro® armband; BodyMedia,
Inc., Pittsburgh, PADL, USA), which was worn on the
upper right arm. The device estimates energy expend-
iture (EE) using measurements from a biaxial accelerom-
eter and sensors that quantify galvanic skin response,
heat flux and skin temperature. The biaxial accelerometer
records the number of steps per day and the duration of
PADL [18]. The number of steps per day, metabolic
equivalent (MET), total energy expenditure (TEE), and
PAL were used in the present study. PAL was calculated
using TEE and sleep expenditure as a surrogate for rest-
ing energy expenditure (REE) (PAL = TEE/REE). The
patients were instructed to wear the accelerometer con-
tinuously during 7 consecutive days, except when bath-
ing or showering. The SenseWear Pro® armband was
validated to accurately measure PADL and quantify EE
in patients with COPD [39-41].
Statistics
A statistical software package was used for all calculations
(SPSS® for Windows, Version 20.0, SPSS Inc., Chicago,
IL, USA). Descriptive data for continuous variables are
expressed as mean, standard deviation and percentages
for frequencies. Variables were tested for parametric
distribution by applying the Shapiro-Wilk Test (null hy-
pothesis rejection set at p < 0.25). Univariate regression
was performed to evaluate a possible association be-
tween QS and measures reflecting PADL derived from
accelerometry, 6MWD, the number of stands during the
STST, and handgrip-strength. The multivariate analysis
was performed to analyse if QS is independently associ-
ated with these measures reflecting PADL and EP. The
multivariate analysis included measures of PADL that
showed significant associations in the univariate regres-
sion analysis, Forced Expiratory Volume in 1 second
(FEV1) and age. A p < 0.05 was considered to indicate
statistical significance.
Results
Figure 1 shows the study profile. Twenty-seven patients
(thirteen females) with COPD and an average age of 62 ±
5 years agreed to take part and were included in the study.
Anthropometrical characteristics and data reflecting pul-
monary function, EP and PADL are presented in Table 1.
Patients reported the following comorbidities: diabetes
mellitus, osteoporosis, hypertension, depression, arth-
ritis, and peripheral arterial disease. Five of participating
subjects declared to be active smokers. The majority of
patients (74.1%) were “at high risk and with high symp-
tom burden” (GOLD D).
Physical activity
In four of the 27 patients PADL data were unavailable
due to technical problems. Therefore, the analysis of
PADL data included 23 patients. The mean PAL of the
patients was 1.44 (0.16) (Table 1); 41% of the patients
had an extremely inactive lifestyle (PAL < 1.4), 55% had
a sedentary lifestyle (PAL 1.40-1.69) and 4% were classi-
fied as moderate to vigorously active (PAL ≥ 1.70). Mean
total energy expenditure (TEEACC) estimated by accel-
erometry was 2222 (467) kcal/day.
Relationship between quadriceps strength, exercise
performance and physical activity
There was a statistically significant positive association
between QS and the 6MWD (Figure 2), the number of
stands during the STST, and handgrip-strength, but not
with PADL as assessed by the SenseWear Pro® armband
(Table 2).
32 patients with COPD screened
29 eligible patients
Data of 27 patients with COPD 
were analysed
2 patients did not consent to 
take part
3 patients did not fulfill the 
criteria
23 patients were included in the 
analysis of physical activity
Figure 1 Study profile.
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The results of the multivariate analyses are shown in
Tables 3, 4 and 5. After correction for age and FEV1, QS
was found to be independently associated with the num-
ber of stands during the STST (β = 0.50, 95% CI 0.11 to
0.86, p = 0.014) and handgrip-strength (β = 0.45, 95% CI
0.05 to 0.84, p = 0.038). Both FEV1 and QS were inde-
pendently associated with the 6MWD (QS: β = 0.42, 95%
CI 0.09 to 0.84, p = 0.019). 52.4% of the variance in
6MWD could be explained by the model (Table 3). QS
explained 50.2% and 45.5% of the variance in the num-
ber of stands during the STST and handgrip-strength,
respectively (Tables 4 and 5).
Discussion
In 27 patients with COPD (GOLD A-D) QS was inde-
pendently associated with the 6MWD, the number of
stands in the STST, handgrip-strength but not with
PADL as assessed by the SenseWear Pro® armband.
It has been recognized that skeletal muscle dysfunction
is a common feature in patients with COPD, and may play
a significant role in morbidity and mortality [42]. Several
authors [19,43,44] have demonstrated that peripheral
muscle weakness may be a major contributor to exercise
limitation in COPD. Killian and colleagues [22] measured
leg effort and dyspnoea in 97 patients with chronic airway
Table 1 Anthropometrical characteristics and pulmonary
function, EP and PADL data of the study group
Variable
Anthropomertrics
Subjects (n) 27
Female/male 11/16
Age (years) 62.3 (5.7)
BMI (kg/m2) 24.5 (5.8)
GOLD-Classification
A 3.7%
B 18.5%
C 3.7%
D 74.1%
Pulmonary function
FEV1 (l) 1.1 (0.6)
FEV1 (% predicted) 37.6 (17.6)
FEV1/FVC (ratio) 0.40 (0.14)
TLC (% predicted) 112.6 (25.4)
RV/TLC 56.8 (10.7)
PaO2 (kPa) 9.5 (1.9)
PaCO2 (kPa) 5.1 (0.5)
Exercise performance
6MWD (m) 390 (103)
Sit-to-Stand Test (n) 20 (7)
Handgrip Test (kg) 33.7 (10.3)
Quadriceps strength (Nm) 14.5 (5.2)
Daily physical activity by accelerometry
PAL (ratio) 1.44 (0.16)
MET (kcal/h/kg) 30.3 (4.7)
TEEACC (kcal/day) 2222 (467)
Steps/day (n) 4097 (2325)
Time <3METs (min) 1341 (876)
Time 3–6 METs (min) 86 (30)
Time >6 METs (min) 0 (2)
Values are presented as mean (SD). BMI, body mass index; DLCO, diffusion
capacity for carbon monoxide; FEV1, forced expiratory volume in one second;
FEV1/FVC ratio, forced expiratory volume in 1 sec (FEV1) expressed as percent
of FVC; MET, metabolic equivalent; PAL, physical activity level; PaCO2, partial
pressure of carbon dioxide; PaO2, partial pressure of oxygen;RV/TLC, residual
volume/total lung capacity ratio; TEEACC, total energy expenditure per day as
assessed by accelerometry; TLC, total lung capacity.
Figure 2 Scatterplot showing the relationship between
quadriceps strength and the 6-minute walk distance, 6MWD
(β = 0.45, 95% CI 0.085 to 0.835, p = 0.018).
Table 2 Associations with quadriceps strength
Variable Coefficient β 95% CI p
Daily physical activity
MET (kcal/24 h/kg) 0.100 −0.371 – 0.582 0.650
TEEACC (kcal/day) 0.274 −0.171 – 0.749 0.206
PAL 0.092 −0.345 – 0.516 0.684
Steps/day (n) −0.085 −0.567 – 0.387 0.699
Exercise performance
6MWD (m) 0.451 0.085 – 0.835 0.018
Sit-to-Stand test (n) 0.502 0.105 – 0.857 0.015
Handgrip test (kg) 0.455 0.050 – 0.837 0.029
Time < 3METs (min) −0.055 −0.811 - 0.434 0.822
Time 3–6 METs (min) 0.449 −0.111 – 1.010 0.080
Univariate regression is expressed as β. 6MWD, 6-minute walk distance, MET,
metabolic equivalent; PAL, physical activity level; TEEACC, total energy
expenditure per day as assessed by accelerometry. P < 5% is significant.
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obstruction during maximal cycle ergometry. Indeed, pa-
tients complained more about leg discomfort than about
dyspnoea after cycle ergometry. In accordance with these
results, in this study we found that QS was independently
associated with exercise performance (EP) as quantified by
several laboratory-based tests.
International guidelines recommend exercise training
to improve skeletal muscle function as an essential com-
ponent of PR in patients with COPD [11,16]. However,
in order to be meaningful for patients with COPD,
improvements in peripheral muscle strength need to be
translated into changes in PADL and participation in
everyday situations. As there is compelling evidence
highlighting the role of muscular strength in the EP in
patients with COPD, it seems reasonable to assume that
impaired muscle strength subsequently leads to difficul-
ties in performing daily tasks and participating in daily
life activities. However, we failed to demonstrate an as-
sociation between QS and any measure reflecting PADL
as assessed by the SenseWear Pro® armband in the pa-
tients of our study.
After reviewing the literature, a total of nine studies,
which investigated the association between QS and PADL
in patients with COPD were found. Out of nine studies
only two [25,27] used a multi-sensor accelerometer to ob-
jectively quantify PADL. Five studies [8,23-26] succeeded
to demonstrate an association between QS and PADL and
four [27-30] failed to demonstrate such association.
In this study QS was independently associated with EP
but not with PADL as assessed by the SenseWear Pro®
armband. Although the design of this study does not
allow to establish a causal relationship between QS and
PADL, these results need to be elucidated. In a previous
research we demonstrated that EP tests do not necessarily
reflect daily activities in patients with COPD accurately
[45]. This may be due to the fact that EP tests evaluate pa-
tients’ true abilities while PADL accelerometers may not.
Differences may depend on personal factors, such as effort
spent, time for leisure activities and motivation, but also
external factors such as the instructions and the encour-
agement given to the participants during EP testing in a
clinical setting [45]. This may explain the fact that QS is
not associated with PADL in the patients of our study.
It should be stressed that correlations do not prove
causal relationships. Interventional studies investigating
the effect of PR- induced improvements in peripheral
muscle strength on daily PADL allow for a more precise
and meaningful examination of the association between
QS and PADL. Although the main purpose of PR should
be enhancing PADL [31], only few studies have investi-
gated the impact of PR on PADL in patients with COPD.
Pitta and colleagues [46] assessed PADL at baseline, after
three months and at the end of a six-month multidiscip-
linary rehabilitation program in 29 patients with COPD.
Although three months of PR improved exercise capacity
and QS, these improvements did not result in patients
spending more time walking in daily life. After additional
three months of PR, PADL did actually increase [46].
However, it would be more powerful to analyse if PR-
induced improvements in QS are associated with improve-
ments in PADL in patients with COPD. In the only study
that addressed this issue [24], PR-induced improvements
in QS did not predict changes in PADL. This is in good
accordance with the findings of the present study, that QS
is not related to the level of PADL in patients with COPD.
Limitations
The present study has certain limitations that need to be
taken into account. The number of subjects is small
given the variance in data. In addition, the majority of
Table 3 Multiple regression analysis of predictors of the
6MWD (m)
Model 1 Coefficient B Std. Error Coefficient β t p
Residual 434.893 162.825 2.67 0.014
Quadriceps
muscle
strength (Nm)
10.02 3.96 0.42 2.53 0.019
FEV1
(% predicted)
2.29 1.04 0.371 2.20 0.038
Age (years) −4.30 2.56 −0.28 −1.68 0.107
6MWD, 6-minute walk distance; FEV1, forced expiratory volume in one second
(r2 = 0.524).
Table 4 Multiple regression analysis of predictors of the
number of stands (STST)
Model 2 Coefficient B Std. Error Coefficient β t p
Residual 14.71 13.19 1.12 0.279
Quadriceps
muscle
strength (Nm)
0.85 0.31 0.50 2.71 0.014
FEV1
(% predicted)
0.15 0.10 0.28 1.52 0.146
Age (years) −0.22 0.19 −0.22 −1.19 0.250
FEV1, forced expiratory volume in one second (r2 = 0.502), STST,
Sit-to-Stand Test.
Table 5 Multiple regression analysis of predictors of
handgrip-strength
Model 3 Coefficient B Std. Error Coefficient β t p
Residual 24.13 18.15 1.330 0.199
Quadriceps
muscle
strength (Nm)
0.96 0.42 0.45 2.23 0.038
FEV1
(% predicted)
0.07 0.11 0.13 0.52 0.517
Age (years) −0.11 0.27 −0.85 −0.42 0.680
FEV1, forced expiratory volume in one second (r2 = 0.455).
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the study population represents GOLD D, which may
affect outcomes. We did not investigate potential exer-
cise performance limiting factors such as hemodynamic
factors, cardiac autonomic nervous system factors, and
psychological factors (motivation, anxiety and depres-
sion). Neither did we control for the use of long-acting
β2-agonists, which may have a small effect on exercise
performance and PADL. Furthermore, because cardio-
pulmonary exercise testing (CPET) is regarded as the
gold standard assessment for evaluating exercise cap-
acity, the tests used in this study may not reflect the true
exercise capacity. It should be stressed that the results of
the STST mainly reflect the performance of lower
extremity muscles.
Conclusions
We conclude that quadriceps strength may be associated
with exercise capacity as assessed by several laboratory-
based tests such as the 6-minutes walking test, the sit-to-
stand test and handgrip-strength. Future well-designed
interventional trials investigating the predominant role of
peripheral muscle strength on daily physical activity are
needed to establish the preliminary finding of the current
study. However, quadriceps strength was not associated
with physical activity levels in patients with COPD. This
may be due to the fact that patients with COPD do not
exhaust their functional abilities during daily living, as they
do during laboratory-based testing.
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